DOCSLIB.ORG

Financial and Non-Financial Highlights Chugai Pharmaceutical Co., Ltd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Financial and Non-Financial Highlights Chugai Pharmaceutical Co., Ltd International Financial Reporting Standards (IFRS) Financial and Non-Financial Highlights Chugai Pharmaceutical Co., Ltd. and Consolidated Subsidiaries/Years ended December 31 Financial Indicators (Core Basis) Results Ratio of cost of sales to sales (%) Ratio of operating expenses to revenues (%) Japanese GAAP IFRS (Core basis) 46.0 46.4 45.4 44.6 43.2 43.1 37.2 37.2 39.5 39.8 40.2 35.8 390.2 Sales (excluding Tamiflu) 357.4 354.7 363.2 (Billions of yen) 342.9 61.1 33.0 9.2% 42.3 11.6% 15.7% 313.4 33.6 9.8% 39.7 11.2% 37.4 30.1 8.3% 28.6 7.3% Overseas 33.5 10.7% 40.9 10.5% 33.7 9.5% 18.8 4.8% 11.9% 25.8 7.2% 20.3 5.6% Others 22.8 6.4% 42.3 13.5% 26.2 7.6% 48.1 48.9 12.5% Transplant, immunology 57.4 50.6 13.2% 24.0 7.7% 16.1% 14.3% and infectious diseases 61.0 60.6 61.3 17.8% 66.3 15.5% Renal diseases 62.6 66.1 18.3% 19.6% 17.5% 18.6% Bone and joint 57.6 16.8% diseases 50.0 16.0% 172.4 141.2 141.8 156.1 Oncology 102.3 123.7 32.6% 36.1% 39.5% 40.0% 43.0% 44.2% 2008 2009 2010 2011 2012 2013 Business process reengineering Budget control Launch of main products in Japan Actemra Edirol Perjeta (rheumatoid arthritis) Mircera Actemra (subcutaneous injection) Bonviva Approval of main products overseas Actemra Actemra Actemra (rheumatoid (rheumatoid (subcutaneous arthritis, E.U.) arthritis, U.S.) injection, U.S.) Chugai product Revenues/ Operating Profit/ Net Income/Core EPS Royalties and Other Operating Income Ratio of Operating Profit to Revenues (Billions of yen/Yen) (Billions of yen) (Billions of yen/%) 76.7 534.2 541.5 103.2 108.0 498.8 491.8 461.1 90.7 64.9 80.6 56.8 147.00 77.3 53.0 19.3 116.42 138.68 18.2 19.9 102.50 43.0 16.8 16.4 95.04 30.4 34.9 24.2 19.1 2014 2015 2016 2017 2018 2014 20152016 2017 2018 2014 2015 2016 2017 2018 (Forecast) (Forecast) (Forecast) Revenues Operating profit Net income Royalties and other operating income Ratio of operating profit to revenues Core EPS Revenues continue to expand, led by increases Chugai’s ratio of operating profit to revenues In mid-term business plan IBI 18, we set a Core in exports of Chugai products and in royalties is consistently high due to the low ratio of EPS compound annual growth rate (CAGR) of and other operating income (ROOI). ROOI is operating expenses to revenues. In 2017, the less than 4 percent as the quantitative outlook, composed of recurring income, which has been increase in ROOI and the higher percentage of with 2015 as the baseline, and are using it as a increasing in conjunction with overseas sales of Chugai products in the sales mix resulted in a key performance indicator shared both internally Actemra, and non-recurring income, which lower ratio of cost of sales to sales, which and externally. In the forecast for 2018, we changes from year to year and is the principal contributed to the increase in the ratio of project that this indicator will be 9.5 percent,1 factor in the fluctuations in ROOI. operating profit to revenues. In 2018, we expect significantly higher than our original plan. record profit for a second consecutive year due to growth of mainstay products and ROOI. 1. Based on average exchange rates for 2015 12 CHUGAI PHARMACEUTICAL CO., LTD. Chugai has substantially improved its cost structure in view of the rising cost of sales 51.0 52.2 49.7 50.7 50.6 to sales ratio resulting from the increase in products in-licensed from Roche under the strategic alliance between the two companies. We have now secured high 36.2 33.9 33.4 33.3 33.5 profitability by continuously achieving a ratio of operating expenses to revenues at a level 482.4 492.9 that compares favorably with the world’s 459.2 460.2 leading pharmaceutical companies. 423.8 94.0 118.1 82.2 79.5 19.5% Sales have grown steadily in the area of 74.3 17.9% 17.3% 24.0% 18.5 4.0% 6.2% 2 17.5% 21.7 4.7% 29.9 27.9 5.7% oncology based on products in-licensed from 15.9 3.5% 13.7 3.0% 25.6 6.0% 41.1 39.3 8.1% 35.3 7.2% Roche as well as Alecensa, a product from 20.8 4.9% 45.4 9.9% 9.0% Chugai’s research. Sales also continue to grow 44.7 10.5% 93.3 79.4 86.1 97.1 in the area of bone and joint diseases, driven 18.8% 19.3% 69.6 17.3% 19.7% 16.4% by Chugai products Edirol and Actemra, the first therapeutic antibody created in Japan. 215.7 220.3 225.9 214.5 188.9 2. Sales of the transplant, immunology and infectious diseases area, which were disclosed separately up until 2016, were included and disclosed in sales of the Others area from 2017. 44.6% 46.9% 48.0% 46.8% 43.5% 2014 2015 2016 2017 2018 (Forecast) Productivity improvement Kadcyla Zelboraf Alaglio Alecensa Actemra Alecensa (U.S.) Hemlibra (U.S., E.U.) （subcutaneous Alecensa (E.U.) injection, E.U.) Exports to Roche/Overseas Sales Ratio Dividends per Share/Core Payout Ratio (Billions of yen/%) (Yen/%) About Core Basis Results Chugai reports its results on a Core 99.6 basis from 2013 in conjunction with 62 62 58 its decision to adopt IFRS. Core 76.4 6 52 48 basis results are the IFRS basis 63.1 62.8 results adjusted by excluding non- 55.1 26.1 49.8 50.7 21.8 44.7 Core items, and are consistent with 23.1 50.5 42.2 19.1 19.6 the concept of Core basis results disclosed by Roche. Core basis results are used by Chugai as internal performance indicators for 2014 20152016 2017 2018 2014 2015 2016 2017 2018 (Forecast) (Forecast) representing recurring profit trends Exports to Roche Annual dividends per share both internally and externally, and Overseas sales ratio Special dividends Core payout ratio (Core EPS basis) as indices for establishing profit distributions such as returns to Chugai product Actemra has grown into a Regarding shareholder returns, we target stable shareholders. No items have been mainstay product of the Roche Group, with dividends with a Core EPS payout ratio of 50 excluded from the IFRS balance global sales (including Japan) surpassing 1.9 percent on average, based on an approach of sheet and cash flows, as the Core billion Swiss francs in 2017. Alecensa, another dividing core net income equally between the basis results concept only applies product from Chugai research, received approval Company and our shareholders. This policy will to the income statement. in Europe and the United States for the continue unchanged under IBI 18, our current additional indication of first-line treatment at mid-term business plan. the end of 2017, and is expected to drive overseas sales. ANNUAL REPORT 2017 13 Research, Clinical Development and Production R&D Expenditures/R&D Expenditures to Revenues/Pipeline Projects R&D expenditures (Billions of yen)R&D expenditures to revenues (%) Number of pipeline projects 88.9 Japanese GAAP IFRS (Core basis) 40 82.6 80.6 81.9 41 37 74.1 39 34 34 70.5 34 66.6 34 30 55.3 53.2 54.7 28 18.9 17.5 17.2 17.5 16.4 16.8 16.3 16.6 12.9 14.4 20082009 2010 2011 2012 2013 2014 2015 2016 2017 Participation in multinational studies Approval and Development of proprietary antibody CPR establishment and business expansion, development engineering technologies out-licensing of Chugai products of Actemra Investment in facilities to handle multiple development projects simultaneously As revenues grow, Chugai increases investment in research and development. Under our strategic alliance with Roche, we have been promoting new drug In addition to the steady creation of innovative drugs, this leads to research development with higher success rates and greater efficiency by collaborating findings that may contribute to the advancement of healthcare and the with Roche in ways such as examining and deciding on which Roche products pharmaceutical industry worldwide. Our policy is to proactively conduct to in-license based on the results of early-stage clinical trials. In recent years, speedy research and development in light of the competitive environment, we have maintained a robust pipeline, with numerous products from Chugai as well as upfront investment to acquire and enhance future competitiveness, research having moved into the clinical phase, including in-house products while keeping growth in overall operating expenses within the rate of revenue from Chugai Pharmabody Research (CPR),1 which has expanded its operations growth as a general principle. to accelerate the creation of innovative therapeutic antibodies. 1. Established in Singapore in 2012 Publications in Academic Papers and New Products Launched and Energy Consumption/ Presentations at Scientific Conferences New Indications/Percentage of Product Energy Consumption per Employee 2 regarding Chugai Research Findings Sales Qualifying for Premium Pricing (Thousands of GJ/GJ per employee) (Number/%) 95 2,384 87 86 78 78 2,184 2,211 2,170 2,185 84 75 73 74 74 5 355 311 308 299 296 3 2 2 2 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 20103 2014 2015 2016 2017 New products launched and new indications Energy consumption Percentage of product sales qualifying for Energy consumption per employee premium pricing Chugai develops innovative medicines that allow Products that qualify for premium pricing As it expands its production system for new it to differentiate itself from competitors by account for a consistently high proportion of drugs by introducing facilities, Chugai is continuously establishing proprietary drug Chugai’s sales.
Load more

Recommended publications
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Genentech Tocilizumab Letter of Authority June 24 2021
    June 24, 2021 Hoffmann-La Roche, Ltd. C/O Genentech, Inc. Attention: Dhushy Thambipillai Regulatory Project Management 1 DNA Way, Bldg 45-1 South San Francisco, CA 94080 RE: Emergency Use Authorization 099 Dear Ms. Thambipillai: This letter is in response to Genentech, Inc.’s (Genentech) request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for the emergency use of Actemra1 (tocilizumab) for the treatment of coronavirus disease 2019 (COVID-19) in certain hospitalized patients, as described in the Scope of Authorization (Section II) of this letter, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes coronavirus disease 2019 (COVID-19).2 On the basis of such determination, the Secretary of HHS on March 27, 2020, declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to Section 564 of the Act (21 3 U.S.C. 360bbb-3), subject to terms of any authorization issued under that section. Actemra is a recombinant humanized monoclonal antibody that selectively binds to both soluble and membrane-bound human IL-6 receptors (sIL-6R and mIL-6R) and subsequently inhibits IL- 6-mediated signaling through these receptors.
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • Tocilizumab in Hospitalised Adults with Covid-19
    This document has been approved for use at [ ] USE OF TOCILIZUMAB IN HOSPITALISED ADULTS WITH COVID-19 INFORMATION FOR PATIENTS, FAMILIES AND CARERS This information leaflet contains important information about the medicine called tocilizumab when used in the treatment of COVID-19. WHAT IS THE POTENTIAL BENEFIT OF It is important you provide your formal consent TOCILIZUMAB FOR COVID-19? before receiving tocilizumab. You can always change your mind about treatment with Tocilizumab belongs to a group of medicines called tocilizumab and withdraw consent at any time. monoclonal antibodies. Monoclonal antibodies are proteins, which specifically recognise and bind to unique proteins in the body to modify the way the WHAT SHOULD THE DOCTOR KNOW immune system works. Tocilizumab has effects on BEFORE TOCILIZUMAB IS USED IN the immune system that may be useful in helping COVID-19? to reduce the effects of severe COVID-19. The doctor should know about: Tocilizumab has been approved in Australia to treat any other conditions including HIV or AIDs, some immune conditions such as arthritis, cytokine tuberculosis, diverticulitis, stomach ulcers, release syndrome and giant cell arteritis. The brand diabetes, cancer, heart problems, raised name is Actemra®. blood pressure or any nerve disease such as Recent clinical trials studying the effectiveness of neuropathy tocilizumab in COVID-19 have been analysed by previous allergic reactions to any medicine Australia’s National COVID-19 Clinical Evidence all medicines including over-the-counter and Taskforce. The Taskforce makes recommendations complementary medicines e.g. vitamins, about when tocilizumab is most likely to be minerals, herbal or naturopathic medicines effective in the treatment of COVID-19.
    [Show full text]
  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics
    REVIEWS Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish1*, Swaminathan Sethu1*, Marie-Christine Bielsky2, Lolke de Haan3, Neil S. French1, Karthik Govindappa1, James Green4, Christopher E. M. Griffiths5, Stephen Holgate6, David Jones2, Ian Kimber7, Jonathan Moggs8, Dean J. Naisbitt1, Munir Pirmohamed1, Gabriele Reichmann9, Jennifer Sims10, Meena Subramanyam11, Marque D. Todd12, Jan Willem Van Der Laan13, Richard J. Weaver14 and B. Kevin Park1 Abstract | Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases. However, unwanted adverse reactions — including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity — pose a challenge to the development of new (and safer) immunomodulatory biologics. In this article, we assess the safety issues associated with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions associated with their use. We also outline how these approaches can inform the development of safer immunomodulatory biologics. Immunomodulatory Biologics currently represent more than 30% of licensed The high specificity of the interactions of immu- biologics pharmaceutical products and have expanded the thera- nomodulatory biologics with their relevant immune Biotechnology-derived peutic options available
    [Show full text]
  • BIOLOGIC THERAPIES ASTHMA DYKEWICZ F BW.Pdf
    11/30/2011 Biologic Asthma Therapies and Individualized Medicine Disclosures Advisory boards Mark S. Dykewicz, MD Merck (advisor, honorarium) Director, Allergy & Immunology Shire (advisor, honorarium) Fellowship Program Director Wake Forest University School of Medicine Editorial boards Winston-Salem, North Carolina USA Allergy & Asthma Proceedings American Journal of Rhinology & Allergy Clinical Reviews in Allergy & Immunology Journal of Angioedema Learning Objective Biological therapies May fill unmet needs, potentially in To better understand the use of biologic subpopulations or phenotypes of patients with modifiers in individualized asthma more severe asthma. treatment. May provide insight into mechanisms of asthma Sheharyar, Durrani, Busse. Biological Therapy for Asthma. ACCP PCCSU Article | 03.15.11 Omalizumab (Anti-IgE) Biologics with action against IgE (omalizumab) Biologic mechanism: Mab against IgE; decreases IgE Cytokines levels; results in down-regulation of IgE receptor IL-4 and/or IL-13 Patient subsets: persistent asthma selected for IL-5 specific IgE to perennial allergen, total serum IgE in Chemokine Receptors specified range CCR3 Benefits: 8 trials (n=3429) Rodrigo. Chest 2011 139:28 CXCR2 decreases in exacerbations, dose of inhaled and oral Transcription Factors corticosteroids, hospitalizations PPARs (peroxisome proliferator-activated receptors) improvement in QOL when used as add-on Rx Prostaglandin Receptors no improvement in lung function. CRTH2 6 1 11/30/2011 IL-4 Modifiers IL-13 Altrakincept Solubilized IL-4 Failed to show efficacy in large phase Pleiotropic cytokine of Th2 cells, promotes IgE receptor fragment, 3 trial. production neutralizes IL-4 Adcock et al (2008) May contribute to key features of asthma Pascolizumab Monoclonal Ab Phase 2 study of pascolizumab IL-13 production inhibited by inhaled glucocorticoids against IL- 4 discontinued because of inefficacy.
    [Show full text]
  • Biological Therapies for Atopic Dermatitis: an Update (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 17: 1061-1067, 2019 Biological therapies for atopic dermatitis: An update (Review) DIANA DELEANU1-3 and IRENA NEDELEA1,2 1Allergology and Immunology Discipline, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, 400058 Cluj-Napoca; Departments of 2Allergy and 3Internal Medicine, ‘Professor Doctor Octavian Fodor’ Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania Received July 6, 2018; Accepted August 22, 2018 DOI: 10.3892/etm.2018.6989 Abstract. Severe atopic dermatitis, which affects both adults in low-income countries (3). Furthermore, the past decades and children, is a debilitating disorder with a significant decline brought a 2-3-fold increase in prevalence in industrialized of patients' quality of life. Although aetiopathogenic factors countries (3). Generally AD onset is in early childhood, as are currently a topic of study and interpretation, the main one of the first steps of the ‘atopic march’, which describes the features of atopic eczema are skin barrier disturbance and natural history of atopic manifestations, and it is character- immune dysregulation. Severe refractory disease that fails to ized by xerotic skin and acute flare-ups of intensely pruritic improve with conventional therapy may benefit from biologic eczematous lesions (4). Recent studies recognize a predilection therapy. Progress in understanding immunopathology of atopic of AD for persistence in adulthood, with a lifetime prevalence dermatitis have allowed identification of therapeutic molecular accounting for 34.1% (5). Early onset, allergic rhinitis and targets in the field of biological therapy. We reviewed the hand eczema in childhood are high-risk factors for persistent different biological treatments with a focus on novel targeted AD (5).
    [Show full text]
  • Tocilizumab in the Treatment of Severe and Refractory Parenchymal Neuro
    TAB0010.1177/1759720X20971908Therapeutic Advances in Musculoskeletal DiseaseJ Liu, D Yan 971908research-article20202020 Therapeutic Advances in Musculoskeletal Disease Case Series Ther Adv Musculoskel Dis Tocilizumab in the treatment of severe and 2020, Vol. 12: 1–8 DOI:https://doi.org/10.1177/1759720X20971908 10.1177/ refractory parenchymal neuro-Behçet’s 1759720X20971908https://doi.org/10.1177/1759720X20971908 © The Author(s), 2020. Article reuse guidelines: syndrome: case series and literature review sagepub.com/journals- permissions Jinjing Liu* , Dong Yan*, Zhimian Wang, Yunjiao Yang, Shangzhu Zhang, Di Wu, Lingyi Peng, Zhichun Liu and Wenjie Zheng Abstract Correspondence to: Objectives: This study aimed to investigate the efficacy and safety of tocilizumab (TCZ) in Wenjie Zheng severe and refractory parenchymal neuro-Behçet’s syndrome (p-NBS). Department of Rheumatology and Clinical Methods: We retrospectively analyzed five patients with p-NBS treated with TCZ in our center Immunology, Peking Union between 2013 and 2020, and six cases from literature research with the index terms “neuro- Medical College Hospital, Chinese Academy of Behçet’s syndrome” and “tocilizumab” on PubMed NCBI. Medical Sciences & Peking Union Medical Results: A total of 11 patients with p-NBS were enrolled (5 males, 6 females), with a mean College, Key Laboratory of age of 34.5 ± 8.0 years at the onset. All the patients had parenchymal neurological lesions, Rheumatology and Clinical Rheumatology, Ministry six patients (54.5%) suffered from multiple lesions, and nine patients (81.8%) were disabled. of Education, National Clinical Research Center Before TCZ administration, all the patients had failed conventional therapy, eight patients for Dermatologic and (72.7%) received two or more immunosuppressants, and five patients showed insufficient Immunologic Diseases, No.
    [Show full text]
  • Tocilizumab Preparation Risk Assessment
    OUH General Risk Assessment Form Tocilizumab Preparation Risk Assessment It is recommended that all Trusts have in place a policy for the handling of mAbs. This should describe the responsibility of the Chief Pharmacist in defining the requirements needed for mAbs prepared outside the pharmacy, the resources available for handling of mAbs within the organisation, the mechanisms in place for the risk assessment of MAB handling and the clinical areas where mAbs may be used. This should be endorsed at Board level within the Trust and include a commitment to provide the resources necessary to allow the safe preparation of mAbs within the Trust in line with the guidance included within this document. It should also address the subject of the cost of provision of the resources required and how these are linked to the costs passed on to commissioners. Site JR Oxford University Hosptials NHS Trust Division CSS Directorate Covid wards/Pharmacy/ICU Department Pharmacy Location Exact N/A Date 21/04/2020 Assessors(s) 1 Clinical Divisional Pharmacist 2 Medicines Safety Pharmacist 3 Preparative Services Pharmacist 4 Senior Pharmacist Manager The Hazard or perceived risk Risks: 1. Risks of exposure to tocilizumab for staff handling the product due to the nature of or mode of action of the agent 2. Risks to patient receiving tocilizumab due to the potential for errors or contamination during the preparation of the product Cause: Need to determine the most appropriate area to prepare tocilizumab based on agreed MAB risk categories Affect: Staff could develop a reaction or adverse effect from tocilizumab. Patients may receive inaccurate product, with risk of microbiological contamination Impact: Minimise potential occupational exposure to staff and risk to patients receiving a dose Description (Identify who will be affected and how; include the context e.g.
    [Show full text]
  • Successful Usage of Combination Biologic Therapy with Etanercept
    Case Report Nov Tech Arthritis Bone Res Volume 2 Issue 4 - Febeuary 2018 Copyright © All rights are reserved by Yoon Kam Hon DOI: 10.19080/NTAB.2017.02.555592 Successful Usage of Combination Biologic Therapy with Etanercept and Actemra for the Treatment of TNF Inhibitor Failure Patients with Rheumatoid Arthritis: A Report of 2 Cases Yoon Kam Hon Department of Arthritis and Rheumatism Specialist Medical Centre, Singapore Submission: January 15, 2018; Published: February 02, 2018 *Corresponding author: Yoon Kam Hon, Consultant Physician And Rheumatologist, El Shaddai Arthritis and Rheumatism Specialist Medical Centre, Block 102 #01-258 Towner Road, Singapore 322102, Tel: +6581258239; Email: Abstract In the treatment of patients with rheumatoid arthritis with anti-tumour necrosis factor therapy, it is not uncommon for some patients to be unresponsive or relapse with treatment. We report the successful usage of combination biologic therapy with etanercept and tocilizumab in two factor and anti-interleukin 6 cytokine therapy in the treatment of rheumatoid arthritis. patients with moderately severe rheumatoid arthritis who failed etanercept therapy. This is the first report of combination anti-tumour necrosis Keywords: Rheumatoid arthritis; Combination biologic therapy; Etanercept; Tocilizumab Introduction therapy inadequate response (IR) RA patients in the RADIATE Rheumatoid arthritis (RA) is a complex chronic autoimmune trial. 50% of patients achieved ACR20 response at week 24, arthritis where many cytokines and chemokines including but only 20% achieved ACR50 response [5]. In the SUMMACTA Tumour Necrosis Factor (TNF), and Interleukin-6 (IL-6) play trial, it was shown that the intravenous (IV) form given at 8mg/ important roles in the pathophysiology of RA.
    [Show full text]
  • Atopic Dermatitis (AD)
    This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by education grants from AbbVie, Inc., Sanofi Genzyme and Regeneron Pharmaceuticals. © 2019 PRIME® Education, LLC. All Rights Reserved.. Overview This downloadable fact‐sheet provides an easy‐to‐follow collection of the latest evidence shaping the treatment and management of psoriasis (PsO) and atopic dermatitis (AD). Learn about validated tools, evidence‐based strategies, and new and emerging targeted therapies that can be incorporated in daily practice to improve outcomes for patients with these conditions. © 2019 PRIME® Education, LLC. All Rights Reserved.. 2 1 Learning Objectives • Identify major barriers to evidence‐based treatment and management in federal and public sectors • Implement appropriate methods for diagnosis and assessment of disease activity • Assess current evidence on targeted biologic and small‐molecule therapies to guide treatment decisions for patients with moderate to severe disease • Monitor treatment responses according to treat‐to‐target principles and methods • Apply current evidence and guidelines to inform treatment decisions for patients with inadequate responses to initial therapies • Incorporate patient‐reported outcomes and shared decision‐making into clinical practice • Apply effective strategies for multidisciplinary care coordination and shared patient management © 2019 PRIME® Education, LLC. All Rights Reserved.. 3 Accreditation In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team, and learners will receive 2.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
    [Show full text]
  • Downloaded Here
    Antibodies to Watch in a Pandemic Dr. Janice M. Reichert, Executive Director, The Antibody Society August 27, 2020 (updated slides) Agenda • US or EU approvals in 2020 • Granted as of late July 2020 • Anticipated by the end of 2020 • Overview of antibody-based COVID-19 interventions in development • Repurposed antibody-based therapeutics that treat symptoms • Newly developed anti-SARS-CoV-2 antibodies • Q&A 2 Number of first approvals for mAbs 10 12 14 16 18 20 Annual first approvals in either the US or EU or US the either in approvals first Annual 0 2 4 6 8 *Estimate based on the number actually approved and those in review as of July 15, with assumption of approval on the first c first the on of approval assumption 15, with as July of review in those and approved actually number the on based *Estimate Tables of approved mAbs and antibodies in review available at at mAbs ofand available in antibodies approved review Tables 1997 98 99 2000 01 02 03 Year of first US or EU approval or EU US of first Year 04 05 06 https://www.antibodysociety.org/resources/approved 07 08 09 10 11 12 13 14 15 Non-cancer Cancer 16 - antibodies/ 17 ycl 18 e. 19 2020* First approvals US or EU in 2020 • Teprotumumab (Tepezza): anti-IGF-1R mAb for thyroid eye disease • FDA approved on January 21 • Eptinezumab (Vyepti): anti-CGRP IgG1 for migraine prevention • FDA approved on February 21 • Isatuximab (Sarclisa): anti-CD38 IgG1 for multiple myeloma • FDA approved on March 2, also approved in the EU on June 2 • Sacituzumab govitecan (Trodelvy): anti-TROP-2 ADC for triple-neg.
    [Show full text]